RTOG initiates a phase I trial testing the therapy ganitumab for locally advanced pancreatic cancer

Public release date: 14-Dec-2011
[ | E-mail | Share ]

Contact: Nancy Fredericks
nfredericks@acr.org
703-648-8936
American College of Radiology

Over 17,000 patients will have been diagnosed with locally-advanced pancreatic cancer in the United States in 2011. Surgery is not a treatment option for these patients whose tumor has grown beyond the pancreas to surrounding vital structures. In the past 20 years, numerous treatment regimens have been evaluated for locally-advanced pancreatic cancer with high-dose chemotherapy followed by chemoradiation being the current standard approach. However, the median survival time of these patients remains generally less than 12 months.

Ganitumab is a fully-human monoclonal antibody antagonist of the insulin-like growth factor-1 receptor, (IGF-1R). From preclinical studies, IGF-1R has been shown to play a significant role in tumor cell growth and in tumor cell's resistance to both chemotherapy and radiation treatment. The investigational drug ganitumab is thought to interrupt the process that changes normal cells into cancer, thereby stopping the abnormal growth behavior of a tumor and making it more amenable to chemoradiation treatment.

"Ganitumab is a therapy under investigation that has shown promising results in early-phase trials for patients with metastatic pancreatic cancer," says Christopher Crane, MD, Professor of Radiation Oncology at MD Anderson Cancer Center and principal investigator for the RTOG 1102 trial, Houston, "Collecting information about the best drug dose and safety of administering ganitumab with chemoradiation is critical to further evaluating the efficacy of this treatment regimen for patients with locally-advanced disease," explains Crane.

Up to 42 study participants at institutions across the United States will be enrolled in the trial and will receive 2 months of induction (high-dose) chemotherapy with gemcitabine and ganitumab to provide early systemic treatment and also to select the study participants most likely to benefit from chemoradiation. Previous RTOG studies, such as RTOG 0411, have shown no increase in toxicity during chemoradiation when induction chemotherapy is first administered.

Following induction chemotherapy, study participants will receive ganitumabfirst investigating doses of 12mg/kg and, if tolerated, subsequently 20 mg/kgalong with standard chemoradiation treatment. Upon treatment completion, participants will continue to receive maintenance doses of gemcitabine and ganitumab until tumor progression.

According to Walter Curran, MD, RTOG Group Chair and Executive Director of the Winship Cancer Institute of Emory University in Atlanta, "Amgen is conducting a phase III trial of ganitumab in metastatic pancreatic cancer. If trial results for treatment of metastatic disease are positive, moving forward with a randomized phase II trial for patients with locally advanced disease would be indicated. In this scenario, the RTOG 1102 trial results will expedite further evaluation of this targeted therapy."

###

For more information, visit RTOG 1102.

The Radiation Therapy Oncology Group (RTOG) is administered by the American College of Radiology (ACR) and located in the ACR Center for Clinical Research in Philadelphia, PA. RTOG is a multi-institutional international clinical cooperative group funded primarily by National Cancer Institute grants CA21661, CA32115 and CA37422. RTOG has 40 years of experience in conducting clinical trials and is comprised of over 300 major research institutions in the United States, Canada and internationally. The group currently is currently accruing to 40 studies that involve radiation therapy alone or in conjunction with surgery and/or chemotherapeutic drugs or which investigate quality of life issues and their effects on the cancer patient.

The American College of Radiology (ACR) is a national professional organization serving more than 32,000 radiologists, radiation oncologists, interventional radiologists and medical physicists with programs focusing on the practice of radiology and the delivery of comprehensive health care services.

http://www.rtog.org

---

[ | E-mail | Share ]

?

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Public release date: 14-Dec-2011
[ | E-mail | Share ]

Contact: Nancy Fredericks
nfredericks@acr.org
703-648-8936
American College of Radiology

Over 17,000 patients will have been diagnosed with locally-advanced pancreatic cancer in the United States in 2011. Surgery is not a treatment option for these patients whose tumor has grown beyond the pancreas to surrounding vital structures. In the past 20 years, numerous treatment regimens have been evaluated for locally-advanced pancreatic cancer with high-dose chemotherapy followed by chemoradiation being the current standard approach. However, the median survival time of these patients remains generally less than 12 months.

Ganitumab is a fully-human monoclonal antibody antagonist of the insulin-like growth factor-1 receptor, (IGF-1R). From preclinical studies, IGF-1R has been shown to play a significant role in tumor cell growth and in tumor cell's resistance to both chemotherapy and radiation treatment. The investigational drug ganitumab is thought to interrupt the process that changes normal cells into cancer, thereby stopping the abnormal growth behavior of a tumor and making it more amenable to chemoradiation treatment.

"Ganitumab is a therapy under investigation that has shown promising results in early-phase trials for patients with metastatic pancreatic cancer," says Christopher Crane, MD, Professor of Radiation Oncology at MD Anderson Cancer Center and principal investigator for the RTOG 1102 trial, Houston, "Collecting information about the best drug dose and safety of administering ganitumab with chemoradiation is critical to further evaluating the efficacy of this treatment regimen for patients with locally-advanced disease," explains Crane.

Up to 42 study participants at institutions across the United States will be enrolled in the trial and will receive 2 months of induction (high-dose) chemotherapy with gemcitabine and ganitumab to provide early systemic treatment and also to select the study participants most likely to benefit from chemoradiation. Previous RTOG studies, such as RTOG 0411, have shown no increase in toxicity during chemoradiation when induction chemotherapy is first administered.

Following induction chemotherapy, study participants will receive ganitumabfirst investigating doses of 12mg/kg and, if tolerated, subsequently 20 mg/kgalong with standard chemoradiation treatment. Upon treatment completion, participants will continue to receive maintenance doses of gemcitabine and ganitumab until tumor progression.

According to Walter Curran, MD, RTOG Group Chair and Executive Director of the Winship Cancer Institute of Emory University in Atlanta, "Amgen is conducting a phase III trial of ganitumab in metastatic pancreatic cancer. If trial results for treatment of metastatic disease are positive, moving forward with a randomized phase II trial for patients with locally advanced disease would be indicated. In this scenario, the RTOG 1102 trial results will expedite further evaluation of this targeted therapy."

###

For more information, visit RTOG 1102.

The Radiation Therapy Oncology Group (RTOG) is administered by the American College of Radiology (ACR) and located in the ACR Center for Clinical Research in Philadelphia, PA. RTOG is a multi-institutional international clinical cooperative group funded primarily by National Cancer Institute grants CA21661, CA32115 and CA37422. RTOG has 40 years of experience in conducting clinical trials and is comprised of over 300 major research institutions in the United States, Canada and internationally. The group currently is currently accruing to 40 studies that involve radiation therapy alone or in conjunction with surgery and/or chemotherapeutic drugs or which investigate quality of life issues and their effects on the cancer patient.

The American College of Radiology (ACR) is a national professional organization serving more than 32,000 radiologists, radiation oncologists, interventional radiologists and medical physicists with programs focusing on the practice of radiology and the delivery of comprehensive health care services.

http://www.rtog.org

---

[ | E-mail | Share ]

?

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Source: http://www.eurekalert.org/pub_releases/2011-12/acor-ria121411.php

best cyber monday deals best cyber monday deals cyber monday grover norquist grover norquist nfl week 12 picks nfl week 12 picks